The company will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, potentially fatal, liver toxicity.
For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat
The company will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, potentially fatal, liver toxicity.